Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

124 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical characterization, prognostic, and predictive values of HER2-low in patients with early breast cancer in the PALLAS trial (ABCSG-42/AFT-05/BIG-14-13/PrE0109).
Nader-Marta G, Singer C, Hlauschek D, DeMichele A, Tarantino P, de Azambuja E, Pfeiler G, Martin M, Balko JM, Nowecki Z, Balic M, Brufsky AM, Chan A, Morris PG, Haddad T, Loibl S, Liu Y, Soelkner L, Fesl C, Mayer EL, Gnant M; PALLAS groups and investigators. Nader-Marta G, et al. Among authors: mayer el. Breast Cancer Res. 2024 Oct 7;26(1):140. doi: 10.1186/s13058-024-01899-2. Breast Cancer Res. 2024. PMID: 39375745 Free PMC article. Clinical Trial.
Adjuvant platinum versus capecitabine for residual, invasive, triple-negative breast cancer: Patient-reported outcomes in ECOG-ACRIN EA1131.
Smith KL, Zhao F, Mayer IA, Tevaarwerk AJ, Garcia SF, Arteaga CL, Symmans WF, Park BH, Burnette BL, Makower DF, Block M, Morley KA, Jani CR, Mescher C, Dewani SJ, Brown-Glaberman U, Flaum LE, Mayer EL, Sikov WM, Rodler ET, DeMichele AM, Sparano JA, Wolff AC, Miller KD, Wagner LI. Smith KL, et al. Among authors: mayer ia, mayer el. Cancer. 2024 May 15;130(10):1747-1757. doi: 10.1002/cncr.35187. Epub 2024 Jan 18. Cancer. 2024. PMID: 38236702
Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030.
Parsons HA, Blewett T, Chu X, Sridhar S, Santos K, Xiong K, Abramson VG, Patel A, Cheng J, Brufsky A, Rhoades J, Force J, Liu R, Traina TA, Carey LA, Rimawi MF, Miller KD, Stearns V, Specht J, Falkson C, Burstein HJ, Wolff AC, Winer EP, Tayob N, Krop IE, Makrigiorgos GM, Golub TR, Mayer EL, Adalsteinsson VA. Parsons HA, et al. Among authors: mayer el. Ann Oncol. 2023 Oct;34(10):899-906. doi: 10.1016/j.annonc.2023.08.004. Epub 2023 Aug 18. Ann Oncol. 2023. PMID: 37597579 Free PMC article.
Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030.
Parsons HA, Blewett T, Chu X, Sridhar S, Santos K, Xiong K, Abramson VG, Patel A, Cheng J, Brufsky A, Rhoades J, Force J, Liu R, Traina TA, Carey LA, Rimawi MF, Miller KD, Stearns V, Specht J, Falkson C, Burstein HJ, Wolff AC, Winer EP, Tayob N, Krop IE, Makrigiorgos GM, Golub TR, Mayer EL, Adalsteinsson VA. Parsons HA, et al. Among authors: mayer el. medRxiv [Preprint]. 2023 Mar 8:2023.03.06.23286772. doi: 10.1101/2023.03.06.23286772. medRxiv. 2023. Update in: Ann Oncol. 2023 Oct;34(10):899-906. doi: 10.1016/j.annonc.2023.08.004 PMID: 36945501 Free PMC article. Updated. Preprint.
A Phase II Study of Atezolizumab, Pertuzumab, and High-Dose Trastuzumab for Central Nervous System Metastases in Patients with HER2-Positive Breast Cancer.
Giordano A, Kumthekar PU, Jin Q, Binboga Kurt B, Ren S, Li T, Leone JP, Mittendorf EA, Pereslete AM, Sharp L, Davis R, DiLullo M, Tayob N, Mayer EL, Winer EP, Tolaney SM, Lin NU. Giordano A, et al. Among authors: mayer el. Clin Cancer Res. 2024 Nov 1;30(21):4856-4865. doi: 10.1158/1078-0432.CCR-24-1161. Clin Cancer Res. 2024. PMID: 39226397 Free PMC article. Clinical Trial.
124 results